WO2003026701A1 - Vectorisation de derives taxoides a travers la barriere hematoencephalique - Google Patents
Vectorisation de derives taxoides a travers la barriere hematoencephalique Download PDFInfo
- Publication number
- WO2003026701A1 WO2003026701A1 PCT/FR2002/003290 FR0203290W WO03026701A1 WO 2003026701 A1 WO2003026701 A1 WO 2003026701A1 FR 0203290 W FR0203290 W FR 0203290W WO 03026701 A1 WO03026701 A1 WO 03026701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivative
- linear peptide
- peptide
- taxoid
- compound according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the use of Taxoid derivatives in the treatment of cancers and more particularly cancers of the central nervous system, very particularly of the brain.
- the invention is also mainly concerned with the transport of taxoid derivatives across the blood-brain barrier (BBB).
- BBB blood-brain barrier
- the subject of the invention is a compound consisting of at least one taxoid derivative linked to at least one vector peptide capable of increasing the solubility of said derivative and advantageously of allowing its transport across the blood-brain barrier.
- the invention also relates to the preparation of these compounds and to the pharmaceutical compositions comprising them useful for the treatment of cancers, especially brain cancers.
- Taxol ® and Taxotère ® have a wide spectrum of clinical activity: their contribution is significant, for the moment, in the treatment of ovarian and breast cancers resistant to anthracyclines.
- One of the preferred targets of this chemotherapy is the microtubules which form a spindle on which the chromosomes migrate at the end of the division of the cell (mitosis).
- the drugs that work on this spindle are antimitotics that block mitosis and prevent cells from reproducing. Taxol acts on the same target, but unlike vinca alkaloids, it stabilizes this spindle and in another way inhibits cell reproduction.
- Taxol and its analogs have the disadvantage of being very sparingly soluble in water. It is therefore generally administered to patients in a solvent (Cremophor EL) which is responsible for hypersensitivity phenomena (allergy). As in most chemotherapies, Taxoids, such as Taxol, cause a decrease in white blood cells and platelets. In addition to its toxicity, it has been described in the literature that Taxol does not pass into the brain and is excluded by the blood-brain barrier (Heimans et al; Ann Oncol 1994, 10 .951-953). All this greatly limits the use of this antimitotic agent for the treatment of several cancers and in particular brain tumors.
- Taxol prodrugs which are metabolized in vivo to release Taxol have been proposed for example in patents and patent applications US 576072, WO
- linear peptide vectors such as linear peptides derived from natural peptides such as Protegrin and Tachyplesin transport active molecules through the BBB and improve the pharmacological properties of these molecules.
- the work and results concerning these linear peptides and their use as vectors of active molecules across the blood-brain barrier have been described in French patent applications No. 98/15074 filed on November 30, 1998 and in the French patent application N ° 99/02938 filed on November 26, 1999.
- the present invention therefore relates to compounds consisting of at least one Taxoid derivative linked to at least one linear peptide capable of increasing the solubility of said derivative and of vectorizing it across the blood-brain barrier.
- a first group of linear peptides used in the context of the compounds of the invention are those comprising a transduction domain.
- transduction domain is meant a peptide sequence capable of penetrating inside the cells.
- transduction domains and in a nonlimiting manner, there may be mentioned:
- MTSs membrane translocation sequences
- ER endoplasmic reticulum
- MTS RE contain 17 to 52 amino acids organized with a positively charged section at the N-terminus, a hydrophobic intersegment and a polar C-terminal region with peptidase recognition sites.
- sequences SEQ ID NO: 3 Gly-Ala-Leu-Phe-Leu-Gly-Trp-Leu-Gly-Ala-Ala-Gly-Ser-Thr-Met-Gly-Ala-Trp -Ser-Gln-Pro-Lys-Lys-Lys-Arg-Lys-Val, or of sequence SEQ ID NO: 4: Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala- Val-Leu-Leu- Ala-Leu-Leu-Ala-Pro.
- a second group of linear peptides according to the invention are derived from Proteins and Tachyplines. Proteins and Tachyplesins are natural antibiotic peptides whose structure is of the hairpin type maintained by disulfide bridges. These bridges play an important role in the cytolytic activity observed on human cells.
- Protinins are used to designate a set of five peptides designated PG-1, PG-2, PG-3, PG-4 and PG-5, the sequences of which are given below, closely related and isolated from pig leukocytes ( VN Kokryakov & col. FEBS lett. 327, 231-236):
- SEQ ID NO: 5 PG-1: Arg-Gly-Gly-Arg-Leu-Cys- Tyr-Cys-Arg-Arg-Arg-Phe-Cys-Val-Cys-Val-Gly-Arg-NH 2
- SEQ ID NO: 6 PG-2: Arg-Gly-Gly-Arg-Leu-Cys- Tyr-Cys-Arg-Arg-Arg-Phe-Cys-Ile-Cys-Val-NH 2
- SEQ ID NO: 7 PG-3: Arg-Gly-Gly-Gly-Leu-Cys- Tyr-Cys-Arg-Arg-Arg-Phe-Cys-Val-Cys-Val-Gly-Arg-NH 2
- SEQ ID NO: 8 PG-4: Arg-Gly-Gly-Arg-Leu-Cys- Tyr-Cys-Arg-Gly-Trp-Ile-Cys-Phe-Cys-Val-Gly-Arg-NH 2
- SEQ ID NO: 9 PG-5: Arg-Gly-Gly-Arg-Leu-Cys-
- Tachyplesins (Tamura, H. et al., 1993, Chem. Pharm. Bul. Tokyo 41, 978-980), designated Tl, T2 and T3 and polyphemusines (Muta, T., 1994, CIBA Found. Sym. 186 , 160-174), designated PI and P2, the sequences of which are given below, are homologous peptides isolated from the hemolymph of two crabs, Tachyplesus tridentatus for the tachyplines Tl, T2 and T3 and Limmulus polyphemus for the polyphemusins PI and P2: SEQ ID NO: 10: PI: Arg-Arg- Trp-Cys-Phe-Arg
- SEQ ID NO: 11 P2: Arg-Arg-Trp-Cys-Phe-Arg- Val-Cys-Tyr-Lys-Gly-Phe-Cys-Tyr-Arg-Lys-Cys-Arg-NH 2 .
- Proteins, tachyplines and polyphemusins contain a high proportion of basic residues (lysines and arginines) and have four cysteines which form two parallel disulfide bridges. These three families of peptides also exhibit homologies with certain defensins and in particular with human defensin NP-1 (Kokryakov, V. N. et al., 1993, Febs Let. 327, 231-236).
- the subject of the invention is therefore a compound consisting of at least one Taxoid derivative linked to at least one linear peptide chosen from the group comprising:
- linear peptide comprising a transduction domain.
- the invention envisages very particularly as linear peptides comprising a transduction peptide chosen, without limitation, from: the transduction domains derived from the Tat protein of HIV1, - the transduction domains derived from the third helix of Antennapedia,
- the invention particularly contemplates as linear peptides derived from Proteins, a peptide which corresponds to the following formula (I):
- Tachyplines a peptide that meets the following formula (II):
- BXXXBXXXBXXXXBBXB (II), in which: - groups B, identical or different, represent an amino acid residue whose side chain carries a basic group, and groups X, identical or different, represent a residue of aliphatic amino acid or aromatic or said peptides of formulas (I) or (II), in retro form, consisting of amino acids of configuration D and / or L, or a fragment thereof consisting of a sequence of at least 5 and preferably at least 7 successive amino acids of the peptides of formulas (I) or (II).
- the invention also contemplates, as linear peptides derived from Proteins, a peptide which corresponds to the following formula (I):
- the groups B which are identical or different, are chosen from arginine, lysine, diaminoacetic acid, diaminobutyric acid, diaminopropionic acid, ornithine, - the X groups, identical or different, are chosen from glycine, alanine, valine, norleucine, isoleucine, leucine, cysteine,
- Taxoid derivatives used in the compounds of the invention include the following:
- Taxol Taxol, Taxotère, or any other derivative of Taxol which is substituted in one or more positions like the positions
- the bond between the Taxoid derivative and the linear peptide in the compounds of the invention is chosen from a covalent bond, a hydrophobic bond, an ionic bond, a cleavable bond or a non-cleavable bond in physiological media or within cells.
- This link can be direct or indirect via a linker (linker) and carried out by means of a functional group naturally present or introduced either on the peptide, or on the Taxoid derivative, or on both.
- This link arm if present, must be acceptable taking into account the chemical nature and the bulk of both the peptide and the Taxoid derivative.
- linkers containing alkyl, aryl, aralkyl or peptide groups esters, aldehydes or acids of alkyl, aryl or aralkyl, anhydride, sulfhydrile or carboxyl groups such as derivatives of l maleymil benzoic acid, maleymil propionic acid and succynimidyl derivatives, groups derived from bromide or cianogen chloride, carbonyldiimidazole, succinimide esters or sulphonic halides.
- Taxoid derivative (s) can be linked by covalent bonds at the level of the N-terminal or C-terminal ends or else at the level of the side chains of the peptide.
- a preferred type of bond between the Taxoid derivative (s) and the linear peptide (s) involves at least one disulfide bridge. Indeed, this type of bond is characterized by its stability in the plasma after injection of the compound, then once the compounds of the invention have crossed the blood-brain barrier, said disulfide bridge is reduced by releasing the Taxoid derivative.
- the binding can be carried out at any site of the peptide as indicated above.
- a subject of the present invention is also a method of treating cancers, particularly brain cancers, consisting in administering to a subject suffering from such cancer an effective amount of a compound previously described.
- the invention therefore relates to a pharmaceutical composition for the treatment of cancers and particularly brain cancers comprising, as active agent, at least one compound described above.
- said pharmaceutical composition is in a form suitable for administration by the parenteral, oral, rectal, nasal, transdermal, pulmonary, central or systemic route.
- linear peptides used in the context of the compounds of the invention are remarkable in that they are capable of solubilizing the Taxoid derivatives in water and thus allowing new formulation of these derivatives capable of increase their effectiveness and reduce side effects.
- a subject of the invention is therefore very particularly a pharmaceutical composition for the treatment of cancers and more particularly of brain cancers comprising at least one Taxoid derivative, characterized in that said taxoid derivative is in the form of a compound soluble in water in which the taxoid derivative is linked to at least one linear peptide as defined above.
- the subject of the invention is also the use of a linear peptide as defined above for solubilizing a Taxoid derivative.
- Another subject of the invention is the use of a linear peptide defined above for the preparation of a medicament intended for the treatment and / or prevention of cancers, said peptide being linked to at least one Taxoid derivative so as to render the latter soluble in water.
- the invention also relates to the use of a linear peptide defined above for the preparation of a medicament intended for the treatment and / or prevention of brain cancers, said peptide being linked to at least one Taxoid derivative to vectorize it. here through the BBB.
- the invention finally relates to the use of a linear peptide for the preparation of a medicament as defined above to be administered to a subject in combination with another anticancer compound such as, without limitation, carmustine, doxorubicin , methotrexate, etc.
- another anticancer compound such as, without limitation, carmustine, doxorubicin , methotrexate, etc.
- FIG. 1 schematically shows the chemical synthesis of a vectorized compound of Taxol.
- FIG. 2 illustrates the passage through the blood-brain barrier of compound 1 (Taxol), compound 2 (Taxol vectorized).
- Taxol 100 mg are dissolved in 1 mL of Dimethylformamide (DMF).
- DMF Dimethylformamide
- succinic anhydride Succ20, 1 eq
- DMAP 1,4-dimethylaminopyridine
- DIEA Diisopropylethylamine
- Test used cytotoxicity test.
- Cells 9L glioblastoma
- MCF-7 and MDA-MB-435 breast cancer
- SK-N-SH nerveroblastoma
- ATCC ATCC's tumor cancer
- the cells are seeded at approximately 10 4 cells per well, 24 h before the addition of the products. They are then at 60-80% confluence on the day of the experiment.
- the cells are kept in culture at 37 ° C. in an atmosphere at 95% humidity and 5% CO 2 in an OptiMem® medium.
- the cells are incubated either with free Taxol or with vectorized Taxol at increasing concentrations for 48 hours to 72 hours.
- the MTT (4, 5-dimethylthiazole-2-yl) - 2, 5-diphenyltetrazolium bromide
- the culture plates are then incubated for 4 hours in 1 oven.
- the resulting crystalline formazan deposit is then dissolved by adding 200 ⁇ l of DMF / SDS.
- the optical density (OD) is measured at 550 nm (reference 630 nm) using a microplate reader.
- the graphic representation of the OD percentages of the wells treated as a function of the concentration of products makes it possible to determine the IC 50 . This corresponds to the concentration of the product inhibiting 50% of growth.
- mice (20-25 g, Iffa-Credo; l'Arbresle, France) are anesthetized.
- the right external carotid artery is linked to the level of bifurcation with the internal carotid artery and the common carotid artery is linked between the heart and the catheter implantation site (polyethylene catheter, ID: 0.76).
- This, previously filled with a heparin solution (100 units / ml) is inserted into the common carotid.
- mice are perfused with the perfusion buffer (128 mM NaCl, 24 mM NaHC0 3 , 4.2 mM KCl, 2.4 mM NaH 2 P0 4 , 1.5 mM CaCl 2 , 0.9 mM MgS0 4 , and 9 mM D-glucose ).
- This buffer is filtered and then bubble by a mixture containing 95% 0 2 /5% C0 2 in order to maintain the pH close to 7.4 and to supply the brain with oxygen during the infusion.
- mice are perfused with the buffer containing free Taxol or vectorized Taxol.
- Taxol is radiolabelled with carbon 14 (specific activity: 55 mCi / mmol, Sigma, France).
- the heart is stopped by section of the ventricles, in order to avoid reflux of the perfusate during the infusion.
- the right hemisphere is then perfused at a speed of 10 ml / min for 60 seconds after which the mouse is decapitated. The amount of radioactivity in the right hemisphere is then measured and the brain penetration (Kin) is calculated.
- Taxol is very insoluble in water or in biological buffers.
- its solubility was more than 10 g / l. This indicates that vectorization significantly improves the solubility of Taxol.
- the sensitivity of cells 9L, MCF-7, MDA-MB- 435 and SK-N-SH to free taxol and vectorized taxol was measured by the MTT test under the experimental conditions defined above for which the relationship between the density optical and the number of viable cells is linear.
- the cells are incubated with increasing concentrations of product and after 24 hours of incubation, the survival of the cells is measured by the MTT test.
- Table 2 represents the concentrations of products causing 50% of growth inhibition (IC 50 ) determined for the free and vectorized Taxol.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02799429A EP1429810A1 (fr) | 2001-09-27 | 2002-09-26 | Vectorisation de derives taxoides a travers la barriere hematoencephalique |
US10/490,357 US20060293242A1 (en) | 2001-09-27 | 2002-09-26 | Transporting of taxoid derivatives through the blood brain barrier |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/12441 | 2001-09-27 | ||
FR0112441A FR2830016B1 (fr) | 2001-09-27 | 2001-09-27 | Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003026701A1 true WO2003026701A1 (fr) | 2003-04-03 |
Family
ID=8867667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/003290 WO2003026701A1 (fr) | 2001-09-27 | 2002-09-26 | Vectorisation de derives taxoides a travers la barriere hematoencephalique |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060293242A1 (fr) |
EP (1) | EP1429810A1 (fr) |
FR (1) | FR2830016B1 (fr) |
WO (1) | WO2003026701A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012076824A1 (fr) | 2010-12-10 | 2012-06-14 | Institut Gustave Roussy | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2786398B1 (fr) | 1998-11-30 | 2002-12-27 | Synt Em | Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide |
US8067376B2 (en) * | 2004-11-03 | 2011-11-29 | Forhumantech Co., Ltd. | Pharmaceutical compositions for transdermal delivery |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
WO2018226992A1 (fr) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Inhibiteur d'agrégation de tau |
US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007728A2 (fr) * | 1997-08-12 | 1999-02-18 | Synt:Em (S.A.) | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
WO2000032236A1 (fr) * | 1998-11-30 | 2000-06-08 | Synt:Em (S.A.) | Vecteurs peptidiques de substances a travers la barriere hemato-encephalique |
WO2000032237A1 (fr) * | 1998-11-30 | 2000-06-08 | Synt:Em (S.A.) | Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide |
WO2001090139A2 (fr) * | 2001-05-07 | 2001-11-29 | Supratek Pharma Inc. | Ligand pour ameliorer l'administration d'agents biologiques par voie orale et via le systeme nerveux central |
WO2002002595A1 (fr) * | 2000-07-03 | 2002-01-10 | Synt:Em S.A. | Peptides lineaires amphipathiques et les compositions les contenant |
-
2001
- 2001-09-27 FR FR0112441A patent/FR2830016B1/fr not_active Expired - Fee Related
-
2002
- 2002-09-26 US US10/490,357 patent/US20060293242A1/en not_active Abandoned
- 2002-09-26 WO PCT/FR2002/003290 patent/WO2003026701A1/fr not_active Application Discontinuation
- 2002-09-26 EP EP02799429A patent/EP1429810A1/fr not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007728A2 (fr) * | 1997-08-12 | 1999-02-18 | Synt:Em (S.A.) | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
WO2000032236A1 (fr) * | 1998-11-30 | 2000-06-08 | Synt:Em (S.A.) | Vecteurs peptidiques de substances a travers la barriere hemato-encephalique |
WO2000032237A1 (fr) * | 1998-11-30 | 2000-06-08 | Synt:Em (S.A.) | Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide |
WO2002002595A1 (fr) * | 2000-07-03 | 2002-01-10 | Synt:Em S.A. | Peptides lineaires amphipathiques et les compositions les contenant |
WO2001090139A2 (fr) * | 2001-05-07 | 2001-11-29 | Supratek Pharma Inc. | Ligand pour ameliorer l'administration d'agents biologiques par voie orale et via le systeme nerveux central |
Non-Patent Citations (2)
Title |
---|
ROUSSELLE, CHRISTOPHE ET AL: "Enhanced delivery of doxorubicin into the brain via a peptide-vector- mediated strategy: saturation kinetics and specificity", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2001), 296(1), 124-131, XP002230865 * |
ROUSSELLE, CHRISTOPHE ET AL: "New advances in the transport of doxorubicin through the blood - brain barrier by a peptide vector-mediated strategy", MOLECULAR PHARMACOLOGY (2000), 57(4), 679-686, XP002230866 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012076824A1 (fr) | 2010-12-10 | 2012-06-14 | Institut Gustave Roussy | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
Also Published As
Publication number | Publication date |
---|---|
EP1429810A1 (fr) | 2004-06-23 |
FR2830016A1 (fr) | 2003-03-28 |
US20060293242A1 (en) | 2006-12-28 |
FR2830016B1 (fr) | 2004-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2219678B1 (fr) | Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse | |
KR20070112762A (ko) | 프리 라디칼 질환 예방 치료용 조성물 | |
FR2960542A1 (fr) | Peptide en tant que medicament, en particulier pour le traitement du cancer | |
WO2014186348A2 (fr) | Nanocomplexes de peptides ou de protéines modifiés | |
EP1379547B1 (fr) | Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation | |
Peng et al. | Glutathione-responsive multifunctional nanoparticles based on mannose-modified pillar [5] arene for targeted antibiotic delivery against intracellular methicillin-resistant S. aureus | |
EP1297001A1 (fr) | Peptides lineaires amphipathiques et les compositions les contenant | |
WO2003026701A1 (fr) | Vectorisation de derives taxoides a travers la barriere hematoencephalique | |
EP1135169B1 (fr) | Utilisation d'une composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide | |
WO2003026700A2 (fr) | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central | |
CA2554822A1 (fr) | Inhibiteurs de l`angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l`angiogenese | |
EP3320342B1 (fr) | Nouveaux hydrogels de structure silylée et procédé d'obtention | |
WO2000007605A1 (fr) | Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite | |
EP1558630A2 (fr) | Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical | |
FR2564096A1 (fr) | Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir | |
KR19990072058A (ko) | 히알루론산 수용체 결합물질과 이의 용도 | |
WO2023247889A1 (fr) | Compositions et méthodes comprenant des peptides pénétrants | |
EP1513557A2 (fr) | Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires | |
FR2976944A1 (fr) | Prodrogues peptidiques | |
FR2834465A1 (fr) | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central | |
FR2782009A1 (fr) | Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite | |
FR2865735A1 (fr) | Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese | |
FR2541578A1 (fr) | Medicament et vaccin pour lutter contre les parasitoses a helminthes, derivant d'un compose ecdysteroide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002799429 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002799429 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006293242 Country of ref document: US Ref document number: 10490357 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10490357 Country of ref document: US |